VCYT Veracyte, Inc.
$50.28▲ +4.32%
Healthcare
Other
After hours
$50.28▲ +0.00%
Oct 27, 4:28 PM ET
Volume 1.81M
Avg Volume (10D) 1.05M
Key Metrics & Fundamentals
Market Cap
$4.04B
P/E Ratio
35.9
Div Yield
0.00%
52W Range
29.46 - 60.91
% vs 50 MA
14.63%
% vs 200 MA
17.74%
RSI-14
65.5
MACD Histogram
+0.6000
Beta (1Y vs SPY)
1.53
Free Cash Flow
$42.97M
Gross Rev
$150.32M
Gross Profit
$108.55M
EBITDA
$31.70M
COGS
$41.77M
Operating Exp
$85.57M
Operating Income
$22.98M
EBIT
$22.98M
Pretax Income
$26.52M
Net Income
$25.49M
EPS (Diluted)
0.31
Price & Volume History
Loading chart…
Recent News
Veracyte Says Data From Decipher Test Predicts Abiraterone Benefit in Prostate Cancer
MT Newswires · Oct 23, 2026 4:53 AM ET
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
GlobeNewswire · Oct 23, 2026 4:00 AM ET
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
Zacks · Oct 21, 2026 11:10 AM ET
What First Trust NYSE Arca Biotech (FBT) Bought: Tarsus Leads on Oct. 16
GuruFocus.com · Oct 20, 2026 7:04 AM ET
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
GlobeNewswire · Oct 19, 2026 8:00 AM ET
Veracyte's Prosigna Breast Cancer Recurrence Test Gets Medicare Coverage
MT Newswires · Oct 16, 2026 9:58 AM ET
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
GlobeNewswire · Oct 16, 2026 9:15 AM ET
Natera Gains 118.1% in a Year: What's Driving the Rally?
Zacks · Oct 15, 2026 8:28 AM ET
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
GlobeNewswire · Oct 14, 2026 4:05 PM ET
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
Zacks · Oct 13, 2026 10:03 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VCYT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.